# AK104 in Neoadjuvant Treatment of Cervical Cancer

> **NCT05227651** · PHASE2 · COMPLETED · sponsor: **Akeso** · enrollment: 14 (actual)

## Conditions studied

- Cervical Cancer

## Interventions

- **DRUG:** AK104

## Key facts

- **NCT ID:** NCT05227651
- **Lead sponsor:** Akeso
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-02-10
- **Primary completion:** 2024-09-27
- **Final completion:** 2024-09-27
- **Target enrollment:** 14 (ACTUAL)
- **Last updated:** 2024-11-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05227651

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05227651, "AK104 in Neoadjuvant Treatment of Cervical Cancer". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT05227651. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*